What Is FTCS? First Trust Capital Strength ETF

Run down the top ten and the absence is the point. As of October 2026 it reads Amgen 2.4%, Garmin 2.4%, Merck 2.4%, ResMed 2.3%, Gilead Sciences 2.3%, Airbnb 2.3%, Vertex Pharmaceuticals 2.2%, CME Group 2.2%, Coca-Cola 2.2% and Johnson and Johnson 2.2%. No Apple, no Microsoft, no NVIDIA, no Amazon, no Alphabet, no Meta. For an investor whose other holdings are cap-weighted, that is unusual and potentially useful, because it is genuinely different exposure rather than a rearrangement of the same names.

Two design choices produce it. The selection screen looks for strong balance sheets, meaning ample cash, modest debt and consistent returns on equity, which favours established profitable businesses over companies whose value rests on future growth. The weighting is then close to equal, so the ten largest positions sit within a fraction of a percentage point of each other, none of them able to dominate.

The sector table follows: financials 27%, industrials 20%, consumer staples 16%, healthcare 15%, consumer discretionary 8%, technology 8%. That is close to an inversion of the modern US market, where technology sits far above every other sector.

The list turns over more than a cap-weighted top ten does. In August it was led by Cisco, Monster Beverage, T. Rowe Price and Automatic Data Processing; by October 2026 only Merck and Johnson and Johnson were still among the ten largest. With every position near the same weight, small price moves and index reviews reshuffle the top of the table, so the names there say more about the screen's latest output than about a lasting core.

Screening on balance-sheet quality is a systematic way of expressing a preference for financial resilience. Companies carrying large cash balances and little debt have more room to absorb a downturn, fund themselves without markets cooperating, and continue investing when weaker competitors cannot. The screen says nothing about valuation, growth rate or industry attractiveness.

That produces predictable characteristics. The portfolio skews toward mature businesses with steady cash generation. In October 2026 the top ten included five drugmakers and biotechs, a medical device maker, an exchange operator, a navigation device maker, a soft drink company and a travel platform. Payouts are moderate, with a distribution yield of 1.22%, because many of these companies favour buybacks and reinvestment alongside dividends.

It also introduces its own risks. Balance-sheet strength is backward looking, and a company can hold plenty of cash while its core business erodes. Equal weighting removes the market's judgment about which businesses deserve the most capital, which cuts both ways depending on whether the market's judgment was right.

At 0.53%, FTCS costs roughly an order of magnitude more than the cheapest large-blend index funds. That is the central question any prospective holder has to answer, because the screen and the equal weighting are rules that can be described in a paragraph, not the product of ongoing research. The fee has to be justified by the difference in exposure over long periods.

The fund is a poor fit for someone who wants US large-cap exposure at the lowest possible cost, where a broad index fund does the job. It is also the wrong tool for anyone who wants participation in the large technology companies driving so much of the market's value, since this fund is constructed to avoid the concentration those companies create. Used alongside a cap-weighted core rather than instead of one, its lack of overlap is the feature.

Equal weighting carries a mechanical cost of its own. Rebalancing back to target means selling what has risen and buying what has fallen, on a schedule, across a portfolio of large companies. That generates turnover a cap-weighted fund never incurs, since a market-value index re-weights itself automatically as prices move. In a taxable account the consequences are worth checking against the fund's own distribution history rather than assumed to be negligible.

Recent results show what the trade looks like in practice. As of October 16, 2026 the fund's price was up 7.5% year to date and 8.2% over one year, with a three-year beta of 0.53, meaning it has moved about half as much as the market over that span. Assets eased from $7.6 billion in August to $7.4 billion. In any period led by the largest technology companies, a fund built to exclude them will tend to trail, and that is the cost of the lower overlap.

Approximate weights as of October 2026. Each ticker links to its individual stock guide in Walnut.

There are three common ways to get FTCS exposure. Buy shares (or fractional shares) of FTCS directly at any major broker that lists it. Hold it as a core position and layer more concentrated ideas on top. Or build it into a thematic portfolio in Walnut, so FTCS sits alongside other holdings that express the same thesis, with target weights you can rebalance toward. FTCS trades like a stock during market hours, so you buy it the same way you would any listed share.

New to buying funds? See how to buy an ETF, step by step.

Whether FTCS is a good buy depends less on any single call and more on your time horizon and what you already hold: it tracks an index of large US companies selected on balance-sheet strength measures such as cash, leverage and return on equity, so the real question is whether you want that exposure in your mix and at what weight. We walk through valuation, concentration, and what would have to be true for it to outperform from here in is FTCS a buy?

FTCS gives you an index of large US companies selected on balance-sheet strength measures such as cash, leverage and return on equity exposure in one ticker at a 0.53% expense ratio. Most investors use it as a core holding and layer more concentrated thematic portfolios on top.

Whether FTCS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, concentration, and what would have to be true for it to outperform from here in is FTCS a buy?

FTCS yields 1.22% as of October 2026, paid by passing through the dividends of its underlying holdings. For the payout schedule, history, and how the distributions are taxed, see FTCS dividend: yield and schedule.

For what analysts expect from the companies FTCS holds, its yield as a guide to income, and why no one publishes a price target for the fund itself, see the FTCS forecast.

New to funds like FTCS? Start with what an ETF is, then how to buy an ETF, or browse the full guide to ETF investing.